Reduction in size of renal angiomyolipoma after treatment with everolimus in lung transplantation due to lymphangioleiomyomatosis

Lymphangioleiomyomatosis (LAM) is a rare disease characterized by abnormal proliferation of immature smooth muscle cells and cystic lung destruction, which determines the prognosis of the disease. The kidney angiomyolipomas are usually very common in this disease and are usually asymptomatic unless...

Full description

Saved in:
Bibliographic Details
Published in:Archivos de bronconeumología (English ed.) 2012-12, Vol.48 (12), p.479-481
Main Authors: Bujalance-Cabrera, Carlos, Vaquero-Barrios, José Manuel, Redel-Montero, Javier, Caballero-Ballesteros, Laura, Requejo-Jiménez, Antonio, Santos-Luna, Francisco
Format: Article
Language:eng ; spa
Subjects:
Adult
Angiomyolipoma - complications
Angiomyolipoma - drug therapy
Angiomyolipoma - pathology
Antineoplastic Agents - therapeutic use
Everolimus
Female
Humans
Kidney Neoplasms - complications
Kidney Neoplasms - drug therapy
Kidney Neoplasms - pathology
Lung Transplantation
Lymphangioleiomyomatosis - complications
Lymphangioleiomyomatosis - surgery
Sirolimus - analogs & derivatives
Sirolimus - therapeutic use
Tumor Burden
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lymphangioleiomyomatosis (LAM) is a rare disease characterized by abnormal proliferation of immature smooth muscle cells and cystic lung destruction, which determines the prognosis of the disease. The kidney angiomyolipomas are usually very common in this disease and are usually asymptomatic unless complications arise. In the absence of a curative treatment, recent publications show promising results in molecular therapy to prevent functional decline and to control the size of the angiomyolipomas. These therapies include mTOR complex inhibitors, especially sirolimus. We report a case of a patient diagnosed with LAM who underwent lung transplantation with reduction of renal angiomyolipoma size after treatment with the mTOR inhibitor everolimus.
ISSN:1579-2129
DOI:10.1016/j.arbres.2012.02.002